ENTPD3 and colorectal carcinoma: According to our unique findings, ENTPD3+ CAFs were not only extremely sensitive but also completely specific in response to truly effective immunotherapy (100% sensitivity and specificity in both cohorts), meaning that MSI-H CRC patients who would benefit from immunotherapy may be well screened by pre-existing ENTPD3+ CAFs.